| Document |
Document Title |
|
WO/2023/167336A1 |
This pharmaceutical composition for treatment or prevention of fibrotic disease contains nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consistin...
|
|
WO/2023/167340A1 |
The present invention relates to a chimeric peptide containing a first domain and a second domain, wherein the first domain contains (i) a peptide containing at least an amino acid sequence shown by any of ID SEQ NOS: 1-4, (ii) a peptide...
|
|
WO/2023/163033A1 |
Provided is a compound that has high binding selectivity to α-synuclein aggregates. The present invention relates to a compound represented by formula (I), (II) or (III), a pharmaceutically acceptable salt thereof, or a solvate of the...
|
|
WO/2023/161440A1 |
The invention relates to human subjects suffering or believed to be suffering from mental exhaustion (synonym with mental fatigue) and possibly aggravated by various manifestations of low energy levels and lack of sleep. The invention pr...
|
|
WO/2023/162903A1 |
The present invention addresses the problem of providing: a liquid that contains a group of exosome-like particles obtained by causing an arbitrarily defined membrane protein to be associated with lipid particles in which the particle si...
|
|
WO/2023/163539A1 |
The present invention relates to a use of a novel pomalidomide derivative which is for treating brain diseases, and exhibits improved pharmacological effects as compared to pomalidomide. The novel pomalidomide derivative according to the...
|
|
WO/2023/161934A1 |
A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. A concentration of the polymer in the composition is at le...
|
|
WO/2023/160520A1 |
The present application provides a preparation method for a trientine tetrahydrochloride crystal. The preparation method comprises: adding an anti-solvent to an aqueous trientine tetrahydrochloride solution at a feeding temperature, and ...
|
|
WO/2023/164386A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/163187A1 |
The present invention provides: an anti-gpNMB antibody that binds to gpNMB and affects the same and that has an effect of such as removal of dysfunctional microglia; and a use application of the anti-gpNMB antibody. The anti-gpNMB antibo...
|
|
WO/2023/164680A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditi...
|
|
WO/2023/163538A1 |
The present invention relates to: a novel pomalidomide derivative exhibiting effects better than those of pomalidomide; a preparation method therefor; and use thereof. The novel pomalidomide derivative according to the present invention ...
|
|
WO/2023/164063A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
|
|
WO/2023/162952A1 |
A method for detecting a marker for diagnosing the disease progression of peritoneal fibrosis, said method involving the detection of the amount of osteopontin present from a peritoneal dialysis drainage fluid used in peritoneal dialysis...
|
|
WO/2023/163992A1 |
Compositions and methos for improving a child, such as an infant's health, are provided. The methods entail improving the quality of breast milk in a female human individual that provides breast milk, or expects to provide breast milk, t...
|
|
WO/2023/163879A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/162987A1 |
Provided are a medicine, a medicinal composition, and a method for the treatment, assistance in treatment, and/or prevention of depression and/or a depressive state, characterized by combining ketamine or a pharmaceutically acceptable sa...
|
|
WO/2023/164464A1 |
The present disclosure provides phosphate mimic derivatives of Formula (I) or (II): (I); (II); pharmaceutically acceptable salts thereof, and related Nucleic Acid Agents and conjugates. The present disclosure also relates to uses of the ...
|
|
WO/2023/163087A1 |
The purpose of the present invention is to provide a medicine exhibiting a satisfactory anti-cancer effect by combining an antibody capable of binding to a mutant CALR protein with another anti-cancer agent. Provided is a medicine for ...
|
|
WO/2023/163971A1 |
The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a...
|
|
WO/2023/163596A1 |
The invention relates to certain chromanol, quinone or hydroquinone compounds and derivatives thereof for treatment or prophylaxis of aging, or idiopathic ageing-associated disorders such as vascular ageing or reduced renal function. Spe...
|
|
WO/2023/164250A1 |
Provided herein are secretion inhibitors, such as inhibitors of Sec61 having a structure of formula (I): methods for their preparation, related pharmaceutical compositions, and methods for using the same.
|
|
WO/2023/164387A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/161326A1 |
The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopat...
|
|
WO/2023/157865A1 |
A rotigotine-containing adhesive patch which comprises a support layer and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer contains at least one compound selected from the group consisting of rotigotine...
|
|
WO/2023/155830A1 |
Disclosed in the present invention are a pyridone or pyrimidone derivative and an application thereof, and particularly disclosed are a compound as shown in formula (VI) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/157948A1 |
The present invention addresses the problem of providing a novel lipid functional ingredient that can be taken or administered orally. An example of a composition containing said ingredient is a composition containing glycerol-1-phosphat...
|
|
WO/2023/157891A1 |
The present invention addresses the problem of providing a drug for use in the treatment of triple-negative breast cancer, providing a blood marker for triple-negative breast cancer, and providing a drug for use in the treatment of infla...
|
|
WO/2023/157776A1 |
In the present invention, it was found that due to the interaction of E-Syt1 on ER with PKCδ in liver cancer cells, PKCδ is secreted from the liver cancer cells by pathways via vesicular transport, and that the secretion of PKCδ from ...
|
|
WO/2023/157895A1 |
The present invention pertains to a prophylactic, therapeutic or inhibitory agent for endometriosis, adenomyosis or dysmenorrhea, said prophylactic, therapeutic or inhibitory agent including a compound having a P2X4 receptor antagonistic...
|
|
WO/2023/157880A1 |
[Problem] To provide a malaria vaccine which has an excellent preventative effect against infection and excellent effect of inhibiting malaria transmission, as compared to conventional malaria vaccines. [Solution] It was found that using...
|
|
WO/2023/156275A1 |
The present invention relates to the simultaneous use of L-tryptophan (L-Try) and L-5-hydroxytryptophan (5-HTP) and a peripheral degradation inhibitor for the prevention and therapy of pain, depression, sleeping disorders and other serot...
|
|
WO/2023/153794A1 |
The present invention relates to a composition for enhancing ovarian function or preventing or treating ovotoxicity. By means of Magnolia Liliflora Bud, Paeonia Lactiflora, Malt, and Astragalus Membranaceus extracts inhibiting the produc...
|
|
WO/2023/153777A1 |
The present invention relates to a composition for hangover relief, the composition comprising a Cucumis melo L. extract as an active ingredient. Specifically, the Cucumis melo L. extract can mitigate an increase in blood ethanol concent...
|
|
WO/2023/154014A1 |
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....
|
|
WO/2023/153020A1 |
One of the problems addressed by the present invention is to provide a cancer-cell proliferation inhibitor that contains a compound that is derived from a food component and that is highly safe. The description of the present application...
|
|
WO/2023/153507A1 |
Provided are: a novel pharmaceutical composition for peritoneal disorders or peritoneal fibrosis accompanied by peritoneal inflammation; and a novel peritoneal dialysis fluid. The present invention provides a pharmaceutical composition...
|
|
WO/2023/151513A1 |
The invention provides novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions (e.g., cancer).
|
|
WO/2023/153479A1 |
A cell population which contains 75% or more of CD11b positive, F4/80 positive, CD180 positive and CD9 positive macrophages derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion, and which contai...
|
|
WO/2023/152499A1 |
The present invention relates to the treatment of telangiectasia, particularly telangiectasia associated with hereditary haemorrhagic telangiectasia (HHT). The present invention provides treatments for telangiectasia associated with HHT,...
|
|
WO/2023/149227A1 |
[Problem] To provide a skin care composition that effectively inhibits elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B) ...
|
|
WO/2023/149411A1 |
The present invention provides a pharmaceutical or food composition for animals, the composition being obtained by combining a first composition and a second composition, and being characterized in that: the first composition contains fi...
|
|
WO/2023/149020A1 |
The present invention addresses the problem of providing a novel treatment agent and/or preventative agent for joint disease. The present invention provides an agent for treating and/or preventing joint disease containing, as an active i...
|
|
WO/2023/148524A1 |
Adipose tissue lipoaspirated or removed from the body, containing mesenchymal stem cells, obtained with a method for promoting the anti- inflammatory properties and for improving the repairing capability, comprising a step of mechanical ...
|
|
WO/2023/149539A1 |
Disclosed is a medical agent that is for treating or suppressing progression of at least one symptom selected from the group consisting of symptoms of amyotrophic lateral sclerosis and symptoms caused by amyotrophic lateral sclerosis in ...
|
|
WO/2023/149226A1 |
[Problem] To provide a skin care composition that effectively inhibits tyrosinase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B...
|
|
WO/2023/149450A1 |
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate,...
|
|
WO/2023/150620A1 |
Compositions and methods for inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a neonatal cell, a population of neonatal cells, or a neonatal subject or for expressing a nucleic acid encoding a po...
|
|
WO/2023/149408A1 |
The present invention provides a cosmetic composition, a cosmetic composition for epidermal keratinocyte proliferation, an epidermal keratinocyte proliferation agent, an antioxidant, a cosmetic composition for dermal papilla cell prolife...
|
|
WO/2023/149443A1 |
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition i...
|
